Pediatric ADHD Study

Centanafadine XR vs. Placebo

$52 per completed visit

Study Specific Details:

  • Centanafadine XR vs Placebo this is a phase 3, multicenter, randomized, double-blind, placebo controlled, study to investigate the treatment effectiveness. Dr. Handal can find out what medication/dose the participant is taking in case of emergency.
  • Blood draws at screening, week 2 and week 6.
  • This is a 6 week trial with 4 week screening period and end of study visit.
  • Participant are reimbursed $52 for their time and travel at the end of each completed visit.
  • Inclusion
  • Exclusion
  • Male or Female ages 4-5.
  • Subject meets DSM-5 criteria for ADHD.
  • Medicine can either be swallowed whole or sprinkled over 1 tablespoon of applesauce.
  • BMI greater or equal to 40 kg or less than or equal to the 5th percentile for age and gender. 
  • IQ is less or equal to 70.
  • Imminent risk of injury to self. 
  • Current or lifetime history of suicidal behavior. 
  • Epilepsy or history of seizures (except for a single episode of febrile seizures - no more than 3).
  • History of sever head trauma. 
  • Tourette's disorder, panic disorder, conduct disorder, PTSD, bipolar, psychosis, autism.
  • Any of the following that is severe enough to interfere with the trial procedures or is the primary focus of treatment: GAD, ODD or OCD.
  • MDD with current major depressive episode or has required treatment within 6 mo. prior to screening.
Questions? Give Us A Call!

Contact Us

Want to learn more about Harmonex Neuroscience Research?

CALL NOW